Eppendorf continues on course for success
The Eppendorf Group successfully ended fiscal year 2016 with Group sales of €651.5 million (prior year: €629.1 million) and revenue growth of 3.6% (4.8% when adjusted for currency effects). Income from operations (EBIT) climbed 17.1% to €139.6 million (prior year: €119.3 million), amounting to an EBIT margin of 21.4% (prior year: 19.0%).
The Asian market and the services segment in particular contributed to this good result. During the reporting year, Eppendorf significantly increased expenses for research and development to €34.8 million (prior year: €31.9 million). In addition, the company expanded its global service and sales presence, among other things through the acquisition of a company in Ireland.
“Once again, we can look back on a good fiscal year. We want to continue developing dynamically and are currently working on a variety of measures to ensure we achieve profitable growth in the future as well,” said Thomas Bachmann, President & Chief Executive Officer of Eppendorf AG. “In addition to carrying out various internal projects, we took the step early this year, for instance, of acquiring a controlling interest in the Dutch company Bio-ITech B.V. after working closely with them last year on device and data networking.”
In 2017, the company will continue to focus on product and application development as well as on the ongoing expansion of its sales, development and production sites.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
